<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02442440</url>
  </required_header>
  <id_info>
    <org_study_id>2015-013</org_study_id>
    <nct_id>NCT02442440</nct_id>
  </id_info>
  <brief_title>Anisodamine Critically Ill SeptIc Shock</brief_title>
  <acronym>ACIdoSIS</acronym>
  <official_title>Effectiveness of Anisodamine for the Treatment of Critically Ill Patients With Septic Shock: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jinhua Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jinhua Central Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anisodamine has been widely used in China for its pharmacological effect on improving
      microcirculation during shock. It has been reported that anisodamine is effective in reducing
      mortality rate in children with meningitis. however, its effectiveness in patients with
      septic shock has not been systematically investigated. The aim of the study is to investigate
      the effectiveness of anisodamine in the treatment of patients with septic shock.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Septic shock is an important contributor of mortality in the intensive care unit (ICU). The
      crude mortality is reported to be from 30% to 65% (1-5). Although there are significant
      advances in the management of septic shock in recent decades, the mortality rate was only
      marginally reduced. For example, the CUB-RÃ©a Network study reported that the mortality rate
      of septic shock declined from 62.1% in 1993 to 55.9% in 2000 (6). The well-known Surviving
      Sepsis Campaign has also made every effort to reduce mortality rate of severe sepsis and
      septic shock. The organization recommended bundled strategies including early goal directed
      therapy (EGDT) for the management of septic shock (7,8). Although EGDT was once the mainstay
      therapy of septic shock, its efficacy has been questioned by recent several large randomized
      controlled trials (9,10). Therefore, the treatment of septic shock is still a global
      challenge and there is no well-established intervention that can reduce its mortality.

      Anisodamine is an active agent isolated from a Chinese herb medicine. Both experimental and
      clinical studies have shown some potential beneficial effects of anisodamine in improving
      outcomes of shock (11-13). It was reported that anisodamine could reduce the mortality rate
      of fulminant epidemic meningitis from 66.9% to 12.4% (14). The efficacy of anisodamine might
      be mediated via the inhibition of thromboxane synthesis, granulocyte and platelet aggregation
      (15). Although anisodamine has been widely used in the treatment of septic shock in mainland
      China, there is no solid evidence from well designed clinical trials to support its efficacy.
      The aim of the study is to investigate the effectiveness of anisodamine in the treatment of
      critically ill patients with septic shock.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hospital mortality</measure>
    <time_frame>from ICU admission to hospital discharge (participants will be followed for the duration of hospital stay, an expected average of 28 days)</time_frame>
    <description>the outcome will be assessed by using proportion of patients died, and relative risk will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>lactate levels</measure>
    <time_frame>from ICU admission to hospital discharge (participants will be followed for the duration of hospital stay, an expected average of 28 days)</time_frame>
    <description>the value was measured in mmol/l, and they will be compared between both arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>anisodamine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administration of the drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>these arm do not use anisodamine, other resuscitation protocol is as usual.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anisodamine</intervention_name>
    <description>Anisodamine will be given first as bolus of 10 mg, followed by 0.1-0.5mg/kg/hr. The adjustment of pump infusion rate is largely at the discretion of treating physician, with the aim of improving microcirculation and limit the side effect to a minimum. For example, if serum lactate continues to elevate, the infusion rate can be increased. Discontinuation on severe side effect or recovery of shock (normalized lactate, weaned from vasopressor) or death.</description>
    <arm_group_label>anisodamine group</arm_group_label>
    <other_name>654-2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with septic shock

        Inclusion criteria included patients with sepsis plus use of vasopressors. Systemic
        inflammatory response syndrome (SIRS) is defined as meeting at least one of the following 3
        criteria for a systemic inflammatory response. One of the SIRS criteria must be either the
        WBC criteria (a) or the body temperature criteria (b):

          1. White blood cell count &gt;12,000 or &lt;4,000 or &gt;10% band forms

          2. Body temperature &gt;38oC (any route) or &lt;36oC (accepting core temperatures only;
             indwelling catheter, esophageal, rectal)

          3. Heart rate (&gt; 90 beats/min) or receiving medications that slow heart rate or paced
             rhythm.

        Suspected or documented infection included the following sites: thorax, urinary tract,
        abdomen, skin, sinuses, central venous catheters, and bacterial meningitis.

        Septic shock was defined as sustained arterial hypotension with systolic blood pressure
        (SBP) &lt; 90 mm Hg, mean arterial pressure (MAP) &lt; 70 mm Hg, or an SBP decrease &gt; 40 mm Hg,
        despite adequate fluid resuscitation. To ease clinical screening process, we defined septic
        shock as the requirement of vasopressors despite adequate fluid resuscitation. Vasopressors
        include norepinephrine, epinephrine, phenylephrine and dopamine&gt;5mcg/kg/min.

        Patients with following conditions will be excluded:

          1. Age&lt;15 years old

          2. Moribund (expected to die within 24 hours)

          3. Stay in ICU for more than 24 hours

          4. Contraindications to anisodamine: elevated intracranial pressure, acute phase of
             intracranial hemorrhage, glaucoma, untreated bowel obstruction (surgically treated
             obstruction is not contraindicated), enlargement of prostate without urinary
             catheterization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>kun chen, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Jinhua Municipal Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>zhongheng zhang, MMed</last_name>
    <phone>8657982553393</phone>
    <email>zh_zhang1984@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Huizhou first hospital</name>
      <address>
        <city>Huizhou</city>
        <state>Guangdong</state>
        <zip>516000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaopeng Feng, MD</last_name>
      <email>fengxiaopeng1977@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Union Hospital, Tongji medical collegue, Huazhong university of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>You Shang, MD</last_name>
      <email>shang_you@126.com</email>
    </contact>
    <investigator>
      <last_name>You Shang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rui Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhouxiong Xing, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuan Yu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shiying Yuan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaojing Zhou, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hong Liu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuanfa Tao</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Huaqing Shu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yaxing Wang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yin Yuan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jiancheng Zhang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiangrong Zuo, MD</last_name>
      <email>13913979197@139.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>affiliated hospital, Jiangsu University</name>
      <address>
        <city>Zhenjiang</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dadong Liu, MD</last_name>
      <email>583837931@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Binzhou People's hospital of Shandong province</name>
      <address>
        <city>Binzhou</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin'an Wang, MD</last_name>
      <email>wangxinan008@163.com</email>
    </contact>
    <investigator>
      <last_name>Rui Yin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>department of critical care medicine, Ren Ji Hospital, School of medicine, Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuetian Yu, MD</last_name>
      <email>fishyyt@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peace hospital of Changzhi medical college</name>
      <address>
        <city>Changzhi</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenhua Zhu, MD</last_name>
      <email>249263735@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caibao Hu, MD</last_name>
      <email>zjicu1996@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>321000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jiancang Zhou, MD</last_name>
      <email>jiancangzhou@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Yucai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jinhua Municipal Central Hospital</name>
      <address>
        <city>Jinhua</city>
        <state>Zhejiang</state>
        <zip>321000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhongheng zhang</last_name>
      <phone>8657982553393</phone>
      <email>zh_zhang1984@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Xuqing Ji, MSc</last_name>
      <email>xuqing_ji@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>kun chen, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiao Xu, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hongying Ni, MMed</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhongheng Zhang, MMed</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xuqing Ji, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of critical care medicine, The central hospital of Lishui City</name>
      <address>
        <city>Lishui</city>
        <state>Zhejiang</state>
        <zip>323000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Tian, MD</last_name>
      <email>xqjytx@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beilun People's hospital; The first affiliated hospital of Zhejiang university (Beilun Branch)</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiping Huang, MD</last_name>
      <email>hnhzhp@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taizhou hospital of Zhejiang province</name>
      <address>
        <city>Taizhou</city>
        <state>Zhejiang</state>
        <zip>317000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chao Zhang, MD</last_name>
      <email>zzcc200@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first People's hospital of Yongkang</name>
      <address>
        <city>Yongkang</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Ren, MD</last_name>
      <email>ykrenbo@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2015</study_first_submitted>
  <study_first_submitted_qc>May 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2015</study_first_posted>
  <last_update_submitted>July 15, 2016</last_update_submitted>
  <last_update_submitted_qc>July 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jinhua Central Hospital</investigator_affiliation>
    <investigator_full_name>Zhongheng Zhang</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>anisodamine</keyword>
  <keyword>septic shock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anisodamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

